NovoCure
NVCR
128 hedge funds and large institutions have $778M invested in NovoCure in 2017 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 43 increasing their positions, 28 reducing their positions, and 10 closing their positions.
352% more call options, than puts
Call options by funds: $20.2M | Put options by funds: $4.46M
240% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 10
54% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 28
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
23% more funds holding
Funds holding: 104 → 128 (+24)
4% more capital invested
Capital invested by funds: $746M → $778M (+$31.9M)
0.87% more ownership
Funds ownership: 42.2% → 43.07% (+0.87%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$22.4M |
| 2 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$17M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$13.5M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$11.6M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$92.1M |
| 2 |
PC
PointState Capital
New York
|
-$14.9M |
| 3 |
AC
Ascend Capital
Orinda,
California
|
-$13M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$9.29M |
| 5 |
JG
Jefferies Group
New York
|
-$6.45M |
NVCR Hedge Fund Activity: Q4 2017 in Review
128 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q4 2017, worth a combined $778M — up 4.3% from $746M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new NVCR positions and 10 closed out — a net gain of 24 holders — while 43 added to existing stakes and 28 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $22.4M. The largest seller was Goldman Sachs, cutting an estimated $92.1M.
- 128 institutional investors held NovoCure (NVCR) as of Q4 2017, up from 104 in Q3 2017.
- Funds reported $778M of NovoCure stock for Q4 2017, up 4.3% quarter-over-quarter.
- 34 funds opened new NovoCure positions in Q4 2017 and 10 closed out, a net change of +24 holders.
- The largest NovoCure buyer in Q4 2017 was Farallon Capital Management, an estimated $22.4M added.
- The largest NovoCure seller in Q4 2017 was Goldman Sachs, an estimated $92.1M sold.
Based on aggregated 13F filings for Q4 2017.